title: Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
authors.affiliation: Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States.
authors.forename: Adepitan A
authors.initials: AA
authors.lastname: Owosho
authors.affiliation: Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States.
authors.forename: Joseph
authors.initials: J
authors.lastname: Randazzo
authors.affiliation: Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States.
authors.forename: Evan B
authors.initials: EB
authors.lastname: Rosen
authors.affiliation: Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States.
authors.forename: Cherry L
authors.initials: CL
authors.lastname: Estilo
authors.affiliation: Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Huryn
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States.
authors.forename: Ping
authors.initials: P
authors.lastname: Chi
authors.affiliation: Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States. Electronic address: kims2@mskcc.org.
authors.forename: SaeHee K
authors.initials: SK
authors.lastname: Yom
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000150:complications*; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000150:complications*; D006801:Humans; D008010:Lichen Planus / Q000150:complications*; D008297:Male; D008545:Melanoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab